Abstract
Defensins and cathelicidins are small cationic peptides produced by neutrophils and epithelial cells. They are highly expressed during infection. The role of constitutive and inducible antibacterial peptides has been extensively studied over the recent years; especially in the gastrointestinal (GI) tract, where the balance between the luminal bacteria and antibacterial peptides is crucial in the maintenance of a healthy GI tract. There are reports showing that the expressions of defensins and cathelicidins in the gut are dysregulated in various disease states. They could participate in the development of different disorders ranging from inflammation to cancer. Experimental findings showed that supplementation with animal cathelicidin promoted gastric ulcer healing in rats and suppressed tumorigenesis of gastric cancer in mice. Mouse cathelicidin could alleviate murine colitis by preserving mucus content and suppression of apoptosis. Other clinical applications for these antibacterial peptides are awaiting for further studies.
Keywords: Defensins, Cathelicidins, Gastritis, Gastric cancer, Inflammatory bowel diseases, neutrophils, peptides, tumorigenesis, metaplasia, magainins, ceropins, in situ, hybridization, hBD-2, hBD-3, hyperexpression, peptidoglycan
Current Pharmaceutical Design
Title: Antibacterial Peptides and Gastrointestinal Diseases
Volume: 17 Issue: 16
Author(s): Clover C. M. Wong, Lin Zhang, Shun X. Ren, Jing Shen, Ruby L. Y. Chan and Chi H. Cho
Affiliation:
Keywords: Defensins, Cathelicidins, Gastritis, Gastric cancer, Inflammatory bowel diseases, neutrophils, peptides, tumorigenesis, metaplasia, magainins, ceropins, in situ, hybridization, hBD-2, hBD-3, hyperexpression, peptidoglycan
Abstract: Defensins and cathelicidins are small cationic peptides produced by neutrophils and epithelial cells. They are highly expressed during infection. The role of constitutive and inducible antibacterial peptides has been extensively studied over the recent years; especially in the gastrointestinal (GI) tract, where the balance between the luminal bacteria and antibacterial peptides is crucial in the maintenance of a healthy GI tract. There are reports showing that the expressions of defensins and cathelicidins in the gut are dysregulated in various disease states. They could participate in the development of different disorders ranging from inflammation to cancer. Experimental findings showed that supplementation with animal cathelicidin promoted gastric ulcer healing in rats and suppressed tumorigenesis of gastric cancer in mice. Mouse cathelicidin could alleviate murine colitis by preserving mucus content and suppression of apoptosis. Other clinical applications for these antibacterial peptides are awaiting for further studies.
Export Options
About this article
Cite this article as:
C. M. Wong Clover, Zhang Lin, X. Ren Shun, Shen Jing, L. Y. Chan Ruby and H. Cho Chi, Antibacterial Peptides and Gastrointestinal Diseases, Current Pharmaceutical Design 2011; 17 (16) . https://dx.doi.org/10.2174/138161211796197025
DOI https://dx.doi.org/10.2174/138161211796197025 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cyclooxygenase-2 Inhibitors: A Painful Lesson
Cardiovascular & Hematological Disorders-Drug Targets Detection of Predictive Markers for Therapeutic Stratification of Salivary Glands Tumors
Current Drug Targets Antioxidant Treatment and Endothelial Dysfunction: Is it Time for Flavonoids?
Recent Patents on Cardiovascular Drug Discovery MicroRNAs and the Response of Prostate Cancer to Anti-Cancer Drugs
Current Drug Targets Biological Active Ingredients of Traditional Chinese Herb Astragalus membranaceus on Treatment of Diabetes: A Systematic Review
Mini-Reviews in Medicinal Chemistry Advances in Translational Pharmacological Investigations in Identifying and Validating Molecular Targets of Natural Product Anticancer Agents
Current Cancer Drug Targets Functional Role of miR-34 Family in Human Cancer
Current Drug Targets MMP Inhibitors in Cardiac Diseases: An Update
Recent Patents on Cardiovascular Drug Discovery Design and Development of Nanoparticulate Dosage Form of Telmisartan for Bioavailability Enhancement
Micro and Nanosystems Medical Management of Obesity
Current Nutrition & Food Science The Position of Endoscopic Procedures in the Treatment of Obesity
Current Clinical Pharmacology Erdafitinib as a Novel and Advanced Treatment Strategy of Metastatic Urothelial Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Histone Deacetylases (HDACs) in Gastric Cancer: An Update of their Emerging Prognostic and Therapeutic Role
Current Medicinal Chemistry Dual-acting of Hybrid Compounds - A New Dawn in the Discovery of Multi-target Drugs: Lead Generation Approaches
Current Topics in Medicinal Chemistry The Role on Endoscopy in Alcohol-Related Diseases
Reviews on Recent Clinical Trials From Concept to Reality: The Long Road to c-Met and RON Receptor Tyrosine Kinase Inhibitors for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry The Role of Obesity in the Development of Polycystic Ovary Syndrome
Current Pharmaceutical Design The Role of YY1 in Oncogenesis and Its Potential as a Drug Target in Cancer Therapies
Current Cancer Drug Targets Inhibitors for Metastasis Development
Recent Patents on Anti-Cancer Drug Discovery Editorial (Thematic Issue: Development of Biomarkers in Tumors of Digestive System Part II)
Anti-Cancer Agents in Medicinal Chemistry